Classification and Application of the Personalized Glioblastoma Organoids

Abstract

The severe survival rate of glioblastoma especially the recurrent glioblastoma, has directly shown the aggressiveness of glioblastoma and meanwhile, showing the lack of the standardized therapies can be effectively and directly against the glioblatoma in clinical situations. The tumor organoids technology has developed rapidly and the personalized glioblastoma organoids have already been used in several researches about the therapies of glioblastoma as an appropriate model. Comparing with the existed models used in past researches, the tumor organoids show irreplaceable features which will contribute a lot in the researches of glioblastoma including the recapitulation of the microenvironment and the cellular communication of parental tumors. In some researches, personalized tumor organoids were used in drug-screening tests and the final-result show high similarity to the actual situations. The drawbacks of common models greatly hamper the development of novel therapies of glioblastoma because of its inaccuracy in the aspects of the recapitulation and experiment results which will prove a invalid therapy in clinical situations as effective and finally deviate the researches from the correct way. Personalized glioblastoma organoids can be divided into 2 types which is the 3D bioprinting organoids and the patient-derived glioblastoma organoids and each of these maintains own advantages in practical situations. Furthermore, personalized glioblastoma organoids can be stored for much more longer time than the existed organoids which also show the possibilities of applying the glioblastoma organoids into the biobank in order to assist further researches.